One of the largest studies ever conducted on the safety of COVID-19 vaccines has become the center of international scientific debate. The research, conducted by the Global Vaccine Data Network, analyzed the health data of over 99 million people from eight countries: Argentina, Australia, Canada, France, Denmark, Finland, New Zealand, and Scotland.
The results were published in the scientific journal Vaccine, a reference point for the international medical community. According to the authors, the majority of vaccinated subjects studied were between the ages of 20 and 59, while the highest number of doses administered was recorded in France.
The vaccines analyzed in the study are those produced by Pfizer, Moderna, and AstraZeneca, the most widely used during the emergency phase of the pandemic. This global observation effort, however, did not allay all concerns. The researchers did, in fact, identify some risk signals associated with vaccine administration.
Specifically, after the first dose of AstraZeneca, an increase in cases of Guillain-Barré syndrome and cerebral venous thrombosis was observed. The former is a neurological condition characterized by progressive muscle weakness, while the latter involves clots that impede normal blood flow. This condition also affected French basketball player Victor Wembanyama in recent months, who was forced to retire for health reasons.
The study also notes that all the vaccines analyzed show a statistically significant increase in the risk of myocarditis and pericarditis, inflammation of the heart muscle and the membranes that cover it. Experts note that these are rare events, but sufficient to warrant further investigation. The authors emphasize that the speed with which the COVID-19 vaccines were developed was a necessary response to an unprecedented situation.
Aby zobaczyć pełną instrukcję przygotowania dania, przejdź następną stronę lub kliknij przycisk Otwórz (>). Not to mention PODZIELIĆ SIĘ nią ze znajomymi on Facebooku.
